0001193125-26-320492
SEC filingCTS 二季度营收增长 7.0%,毛利率大幅提升至 41.5%,但有效税率上升拖累净利增速。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Net Sales | $144,780K | $135,309K | +7.0% |
| Gross Margin | $60,048K | $52,431K | +14.5% |
| Gross Margin % | 41.5% | 38.7% | +280 bps |
| Operating Earnings | $26,801K | $22,731K | +17.9% |
| Operating Margin % | 18.5% | 16.8% | +170 bps |
| Net Earnings | $19,164K | $18,527K | +3.4% |
| Diluted EPS | $0.66 | $0.62 | +6.5% |
| Operating Cash Flow (H1) | $50,735K | $43,870K | +15.6% |
| Free Cash Flow (H1) | $41,158K | $36,125K | +13.9% |
Q2 营收增长 7.0% 至 $144.8M,主要受医疗 (+45.2%) 和工业 (+15.8%) 终端市场强劲增长驱动,而 Aerospace & Defense 因合同授予时点下滑 14.9%,Transportation 小幅下降 2.3%。汇率变动(净对冲后)贡献约 $1.4M 营收增量。
毛利率大幅提升 280 bps 至 41.5%,得益于终端市场组合改善、运营效率提升以及汇率有利影响(约 $1.0M)。SG&A 费用率上升至 19.6%,主要因激励薪酬增加及去年同期收购 earnout 负债减少。R&D 费用下降 24.7%,因一次性客户报销 $1.6M。
净利增速 (+3.4%) 显著低于营业利润增速 (+17.9%),主因有效税率从 19.4% 升至 27.0%(对税收抵免计提 valuation allowance)。剔除一次性项目后,run-rate 盈利能力改善明显。
| 分部 | 营收 | 同比 | 驱动 |
|---|---|---|---|
| Transportation | $59,251K | -2.3% | 小幅下滑 |
| Industrial | $39,508K | +15.8% | 持续增长 |
| Medical | $27,849K | +45.2% | 强劲增长 |
| Aerospace & Defense | $18,172K | -14.9% | 合同授予时点 |
| 项目 | 本期 | 上期/变化 |
|---|---|---|
| Cash & cash equivalents | $107,536K | $82,295K (+$25,241K) |
| Total debt | $55,000K | $57,500K (-$2,500K) |
| Inventory | $59,588K | $52,854K (+$6,734K) |
| Operating Cash Flow (H1) | $50,735K | $43,870K |
| Capex (H1) | $9,577K | $7,745K |
| Free Cash Flow (H1) | $41,158K | $36,125K |
Net Debt = $55,000K - $107,536K = -$52,536K(净现金)。FCF 转化率 = $41,158K / $36,361K ≈ 113%。
关注点: